Brain Tumor Targeted Therapeutic Development Services

Targeted therapy for brain tumors

Targeted drug therapy specifically targets specific abnormalities in cancer cells. By preventing these abnormalities from appearing, targeted drug therapy can kill the cancer cells. Targeted therapy drugs are used to treat certain types of brain tumors. Although there are still relatively few approved targeted drugs in brain tumors, as clinical trials continue, more and more targeted drugs are showing good results in brain tumors, which means that the more likely it is that patients can be matched with targeted drugs through multigene testing.

We provide targeted therapy development services for brain tumors

Brain tumor drug target identification and validation

Alfa Cytology identifies promising targets in early drug discovery. We develop and implement high-throughput target ID screens that characterize a wide range of analytes from small molecular fragments to biologics. We utilize non-labeled binding technologies such as bio-layer interference (BLI) and surface plasmon resonance (SPR) systems to rapidly establish high-throughput binding screens. Our services can be used to identify binding targets and accurately characterize complex formation rates, complex stability, and affinity.

Brain tumor drug development targeting treg cells

Alfa Cytology focuses on the role of Tregs in immunosuppression. We can provide drug development services for Tregs targets, mainly through monoclonal antibodies targeting Tregs and small molecule antagonists targeting Tregs. For this important new immune target in brain tumors, we have also developed a relevant drug target cell screening model for the binding capacity and activity of large and small molecule drugs targeting Tregs.

Brain tumor drug development targeting EGFR

EGFR is often overexpressed and out of control in brain tumors and is, therefore, a hot topic for brain tumor diagnostic and therapeutic research. Alfa Cytology provides drug development services for brain tumors targeting EGFR. We are also developing EGFR-targeting nanotechnology approaches for drug delivery, as well as antibodies targeting extracellular EGFR and potential anti-EGFR antibody-drug conjugates, to provide new avenues for brain tumor treatment.M

Brain tumor drug development targeting angiogenesis

Alfa Cytology focuses on anti-angiogenic therapies, and we provide targeted brain tumor drug development services targeting angiogenesis, particularly VEGF, to inhibit the proliferation of brain tumors, including GBM, by inhibiting the formation of new tumors blood vessels using angiogenesis inhibitors and drugs. Taking the VEGF target as an example, we have a full range of human anti-VEGF antibodies and can provide humanized monoclonal antibodies and anti-VEGF/VEGFR fusion protein development services against VEGF.

Brain tumor drug development targeting epigenetic genes

Drugs that exert anti-brain tumor effects by modulating epigenetic genes are becoming a hot topic of research. Alfa Cytology provides epigenetically targeted drug development services for clients in the field of brain tumor research. Given many potential targets, we have developed a systematic approach to discover and validate potential drug targets to focus on helping our clients in brain tumor drug development and improving drug efficacy.

Brain tumor drug development targeting siRNAs

Alfa Cytology offers brain tumor drug development services targeting siRNAs using multiple development strategies and providing clients with diverse development targets. In addition, we are also trying to chemically modify siRNAs to improve their resistance to nuclease degradation and enhance the stability of siRNAs without affecting their efficacy. We can encapsulate siRNA in nano-delivery bodies such as liposomes, inorganic nanocarriers, or polymeric materials such as dendrimers and polymeric micelles to improve siRNA stability.

Although the treatment options for brain tumor patients are still severely limited and the molecular targeting of brain tumors is very complicated. However, Alfa Cytology, as a leader in the field, has not given up on bringing more therapeutic avenues to our clients in the brain tumor field. We are always ready to find specific genes as promising targets for molecularly targeted brain tumor therapy for you. Please feel free to contact us to learn how we can do this for you.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.